Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Walter V. Klemp
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 1.92
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -19.64
Financials
Net Income
$-7.63MEBITDA
$-7.56MFree Cash Flow
$-6.66MEPS (diluted)
$-1.40Shares Outstanding (diluted)
5.68M+4315.4%Operating Expenses
$7.55MCash & Debt
$7.26MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-33.56M | $-28.42 |
| 2024 | $0.00 | $-21.76M | $-189.14 |
| 2023 | $0.00 | $-29.77M | $-376.71 |
| 2022 | $0.00 | $-29.02M | $-380.51 |
| 2021 | $0.00 | $-15.89M | $-221.77 |
| 2020 | $0.00 | $-17.36M | $-661.00 |
| 2019 | $0.00 | $-13.21M | $-729.63 |
| 2018 | $0.00 | $-11.88M | $-1031.54 |
| 2017 | $0.00 | $-9.80M | $-1188.07 |
| 2016 | $0.00 | $-3.93M | $-900.00 |
| 2015 | $0.00 | $-748.4K | $-117.97 |
Valuation
MBRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·8d ago·Neutral
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
View source ↗ - Newsglobenewswire.com·10d ago·Positive
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin's antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity
View source ↗ - Newsglobenewswire.com·13d ago·Positive
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040 Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference - Video webcast now available here
View source ↗ - Newszacks.com·42d ago·Positive
Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·53d ago·Negative
… into the first quarter of 2027 Absence of cardiotoxicity continues in the MIRACLE trial HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress in its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML). Moleculin continues to advance the pivotal Phase 2/3 MIRACLE trial f…
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.44 per share
Typical surprise -25.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-1.40 vs $-1.55beat
- Thu, May 14$-3.54 vs $-1.69miss
- Fri, Mar 20$2.61 vs $-7.77beat
- Thu, Nov 13$-17.02 vs $-5.00miss
- Tue, Aug 12$-12.25 vs $-9.75miss
- Wed, May 14$-17.25 vs $-17.75beat
Estimates and results for MBRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MBRX officers and directors.
- Bought
- $2.1m
- Sold
- —
9 trades
0 trades
- Foster Jonathan P.bought
- Foster Jonathan P.bought
- Klemp Walter Vbought
- Picker Donald Hbought
- Picker Donald Hbought
- Foster Jonathan P.bought
- Foster Jonathan P.bought
- Klemp Walter Vbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MBRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.